Murine IgG1 anti-CD66 (CEACAM) monoclonal antibody conjugated with the beta-emitting radionuclide Yttrium-90 to deliver targeted radiation to CD66+ myeloid/granulocytic cells in bone marrow and spleen for marrow-directed myeloablation.
Murine IgG1 anti-CD66 (CEACAM) monoclonal antibody conjugated to the beta-emitting radionuclide Yttrium-90; upon binding CD66+ myeloid/granulocytic cells in bone marrow and spleen, it delivers localized radiation that induces DNA damage and cell death, effecting marrow-directed myeloablation and reducing leukemic burden with limited exposure to other tissues.
The Y-90–labeled anti-CD66 (BW250/183) antibody binds CEACAM6 (CD66c) on target cells and delivers beta radiation that induces DNA damage (double‑strand breaks) leading to cell death.
Murine IgG1 anti-CD66 (CEACAM) monoclonal antibody conjugated with the beta-emitting radionuclide Yttrium-90 to deliver targeted radiation to CD66+ myeloid/granulocytic cells in bone marrow and spleen for marrow-directed myeloablation.
Murine IgG1 anti-CD66 (CEACAM) monoclonal antibody conjugated to the beta-emitting radionuclide Yttrium-90; upon binding CD66+ myeloid/granulocytic cells in bone marrow and spleen, it delivers localized radiation that induces DNA damage and cell death, effecting marrow-directed myeloablation and reducing leukemic burden with limited exposure to other tissues.
The anti-CD66 (CEACAM) antibody BW250/183 binds CEACAM1 (CD66a) and delivers Yttrium-90 beta radiation to the bound cells, causing DNA damage (double-strand breaks) and cell death, with some crossfire to nearby cells.
An antibody–drug conjugate (POLIVY) consisting of a humanized anti‑CD79b IgG1 monoclonal antibody linked to the cytotoxic payload monomethyl auristatin E (MMAE), a microtubule inhibitor. It binds CD79b on B cells, is internalized, and releases MMAE intracellularly to disrupt microtubules, leading to mitotic arrest and apoptosis of malignant B cells in DLBCL.
Humanized anti‑CD79b IgG1 antibody conjugated via a protease‑cleavable linker to monomethyl auristatin E (MMAE). After binding CD79b on B cells and internalization, MMAE is released intracellularly, inhibits tubulin polymerization, induces G2/M mitotic arrest, and triggers apoptosis of malignant B cells.
The ADC binds CD79b on B cells, is internalized, and releases MMAE intracellularly; MMAE inhibits tubulin polymerization, causing G2/M arrest and apoptosis of the target cell.
Anti-CD2 monoclonal antibody (also known as TCD601) used peri-transplant for in vivo T-cell depletion to reduce GVHD and graft failure; targets CD2 on T and NK cells.
Humanized IgG1 anti‑CD2 monoclonal antibody that binds CD2 on T and NK cells and induces immune‑mediated cytotoxicity (ADCC/CDC), depleting CD2+ lymphocytes and suppressing T‑cell activity to reduce GVHD and graft rejection.
Siplizumab binds CD2 on target cells and recruits immune effectors via its Fc to trigger ADCC and complement-dependent cytotoxicity, leading to lysis/depletion of CD2+ cells.
Autologous T lymphocytes genetically engineered to express a chimeric antigen receptor targeting CD19 on B cells; administered as cellular immunotherapy for B‑cell malignancies.
Autologous T lymphocytes engineered to express a chimeric antigen receptor that recognizes CD19 on B cells. CAR signaling via CD3ζ and costimulatory domains (e.g., 4-1BB or CD28) upon CD19 binding triggers T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytolysis of CD19-positive malignant B cells, frequently causing B-cell aplasia.
CAR T cells bind CD19 on target cells, form an immune synapse, and induce killing via perforin/granzyme release (and death receptor signaling), leading to apoptosis of CD19-positive cells.